Intravesical BCG injection following transurethral resection (TUR) is the standard of care for treating high-risk superficial bladder cancer (Shelley et al., 2000). BCG decreases the likelihood of tumor recurrence and progression after TUR (Shelley et al., 2000; Lamm, 2000). The antitumor effect of BCG is driven by its T-cell mediated inflammatory response. This inflammatory response is also hypothesized to cause iatrogenic cystitis with dysuria, urinary frequency and low grade fever.
MAA following BCG treatment are rare. The overall incidence of MAA is also relatively low and account for 0.7% to 4.5% of all aortic aneurysms (Oderich et al., 2001). Both our patients presented with vague constitutional symptoms such as epigastric discomfort, weight loss, low grade fevers, and night sweats. Importantly, their presentation to ED was, 6 months and 4 months respectively, after their last BCG instillations. As discussed, CT exams in both cases at the time of emergency presentation showed irregular centrally cystic and peripherally enhancing periaortic collections with inflammatory stranding. These collections were new since compared to pre-treatment staging CT exams. While metastatic periaortic lymphadenopathy was considered in the differential diagnosis, the absence of a primary lesion or other metastases on PET/CT, supported an infective cause. Although patient A had a prior history of TB exposure, the lack of active TB elsewhere in the body, supported the diagnosis of MAA due to BCG therapy. Patient B had no history of prior TB exposure. Pathology from CT-guided biopsy of both cases was consistent with granulomatous infection secondary to their recent BCG therapy. M bovis from recent BCG therapy was cultured in patient A. In patient B, although the percutaneous biopsy did not yield M Bovis, it was cultured from the resected gross specimen.
Several different mechanisms have been postulated for the development of a MAA. These include infection of atherosclerotic intima, bacteremic spread through the vasa vasorum, contiguous spread from a gastrointestinal source, direct extension from vertebral osteomyelitis, or infection of a congenital abnormality such as aortic coarctation (Feigl & Feigl, 1986). In both our cases, there was no imaging evidence of tuberculosis elsewhere in the body. Blood cultures were negative for any systemic pathogens. Neither of the two patients were on chemotherapy or on any immunosuppressant drugs – both risk factors for the development of systemic tuberculous disease. Therefore, we suspect the thoracic and abdominal mycotic aneurysms in our respective patients were a result of M bovis contiguously spreading through the vasa vasorum resulting in thinning of the tunica intima, media and adventitia, and therefore resulting in mycotic aneurysms/pseudoaneurysms.
Surgical resection and debridement of infected aorta followed by an interposition graft or extra-anatomic bypass and long-term antibiotic therapy remain the gold standard management strategy (Muller et al., 2001). However, given the high post-surgical mortality ranging between 13.3–40% (Muller et al., 2001; Kyriakides et al., 2004), endovascular aortic repair (EVAR) remains a popular treatment of choice. Our first patient with an infected thoracic MAA was treated with a thoracic endovascular aortic repair (TEVAR), and the second one was treated with an open surgical resection along with an autologous venous bypass graft. Currently no consensus guidelines exist with respect to choosing EVAR versus open surgical repair. Therefore, a case by case decision needs to be made. Although EVAR has been shown to decrease the overall surgical morbidity and mortality (Kan et al., 2007), placing an endovascular graft in an infected vascular bed can lead to chronic graft infection. A recent multicenter trial demonstrated a 27% infection related complication in post-EVAR treatment of MAA despite continuous antibiotic treatment, with a 19% mortality rate from infection related complications (Sörelius et al., 2014). Given the multiple chronic medical conditions of our patient A, he was deemed a poor surgical candidate and was treated with TEVAR. He had an unremarkable post-procedural course and continues to be asymptomatic. His BCG treatment regimen is complete and has not received any BCG instillations since his TEVAR. Apart from his urothelial carcinoma, patient B was otherwise a healthy patient and a good surgical candidate. Open surgical repair with debridement of infected tissues and a reduction in infection in the vascular bed remains the gold standard for treatment. Patient B underwent surgical excision of the infected abdominal aorta with an autologous graft from the superficial femoral vein and continues to do well in the postoperative period with no relapse.
Given the relative rarity of MAA secondary to BCG treatment in the context of TCC, a complete understanding of BCGosis and best treatment options in these cases is limited. More work is required in understanding the pathophysiology of intravesical BCG causing aortitis as opposed to disseminated systemic BCGosis. Although no predisposing factors were identified in our patients that made them vulnerable to aortitis and MAAs, further investigation into genetic factors and predisposing aortic morphology, such as pre-existing atherosclerotic plaque is required. It is also important to note that the presentation of both these patients was remote from their last intravesical BCG instillation and speaks to the latent nature of BCG related infections. Post treatment, these index patients will be regularly followed up by urology, internal medicine, and vascular teams on a routine basis. The post-operative changes will be assessed with CT angiography and contrast enhanced ultrasound examinations on a routine basis.